# A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

> **NCT02200718** · PHASE1 · UNKNOWN · sponsor: **Immune Response BioPharma, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** NeuroVax
- **BIOLOGICAL:** IFA Incomplete Freund's Adjuvant

## Key facts

- **NCT ID:** NCT02200718
- **Lead sponsor:** Immune Response BioPharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-31
- **Primary completion:** 2024-11-09
- **Final completion:** 2024-11-09
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2020-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02200718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02200718, "A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02200718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*